New combo offers hope for kids with resistant cancers

NCT ID NCT03585465

First seen Jan 25, 2026 · Last updated May 11, 2026 · Updated 9 times

Summary

This study tests a combination of the immunotherapy drug nivolumab with low-dose chemotherapy in children and teenagers whose solid tumors have not responded to standard treatments. The goal is to see if the combo is safe and can help control the cancer longer. About 63 participants are expected, and the study is currently active but no longer recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILDHOOD SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Centre Léon Bérard (IHOPe)

    Lyon, France

  • Centre Oscar Lambret

    Lille, France

  • Cliniques Universitaires Saint-Luc (CUSL)

    Brussels, Belgium

  • Hôpital La Timone, AP-HM

    Marseille, France

  • Hôpital Mère-Enfant, CHU Nantes

    Nantes, France

  • Hôpital d'Enfants - CHRU Nancy

    Nancy, France

  • Hôpital de Hautepierre, CHRU Strasbourg

    Strasbourg, France

  • Hôpital des Enfants - CHU Toulouse

    Toulouse, France

  • Institut Curie

    Paris, France

  • University Hospital Ghent

    Ghent, Belgium

  • University Hospital Leuven

    Leuven, Belgium

Conditions

Explore the condition pages connected to this study.